云顶新耀医药科技有限公司 EVEREST MEDICINES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer 2022-01-04 08:00
Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program 2021-12-20 20:55
Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy 2021-12-16 08:49
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea 2021-12-15 08:00
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant 2021-12-01 08:00
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index 2021-11-24 08:00
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index 2021-11-24 08:00
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint 2021-11-11 08:05
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program 2021-11-08 08:15
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program 2021-11-08 08:10
Everest Medicines Announces Share Repurchase Transaction Details 2021-11-01 08:00
Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections 2021-09-29 17:44
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206 2021-09-24 13:56
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies 2021-09-23 06:00
Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases 2021-09-17 06:30
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets 2021-09-13 17:00
Everest Medicines Announces Half-Year 2021 Interim Results 2021-08-30 22:15
Everest Medicines Announces Up to HK$100 million Share Repurchase Program 2021-08-30 22:03
Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer 2021-08-26 21:40
Everest Medicines to Announce Half-Year 2021 Interim Results 2021-08-23 15:20
1 3 4 5 6 7